Diabetes Drugs Market Status 2018-2022
The global diabetes market has been growing steadily in recent years, with the global diabetes drug market reaching USD 83 billion in 2018 and is expected to exceed USD 124 billion by 2022.

Global Diabetes Market Size and Growth 2015-2022
The U.S. dominates the global diabetes drug market due to the large number of people suffering from diabetes. According to the World Health Organization, 9.6% of the total U.S. population was suffering from diabetes in 2016. In addition to this, increasing number of obesity, changing lifestyle, and increasing healthcare expenditure are contributing to the growth of the U.S. diabetes medication market. Elevated cholesterol levels and smoking increase the likelihood of developing diabetes. According to the CDC (2014), 73.5 million adults in the U.S. have been diagnosed with high cholesterol levels. In addition, increasing awareness about different monitoring procedures, increased awareness, and development of advanced technologies are also contributing to the growth of the diabetes medications market.
Europe is the second largest market for diabetes medications, followed by Asia Pacific. The large smoking population, availability of research funding, and government support for research and development will drive the diabetes drugs market in Europe.
Asia Pacific is the fastest growing region in the diabetes drugs market, attributed to the large patient population, continuous economic development, and increasing demand for better treatments.
On the other hand, the Middle East and Africa has the least share in the global diabetes drugs market due to the economic downturn, especially in Africa. The Middle East holds a major share of the diabetes drugs market in the Middle East and Africa due to a well-developed healthcare sector and huge healthcare expenditure.
2026-08-24
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
China State Drug Administration officially approved Semaglutide for type 2 diabetes
-
Diabetes Drugs Market Competitive Landscape
-
Spain Authorizes Emergency Use of Sulfoxaflor Formulation to Combat Cabbage Whitefly Outbreak
-
EFSA Evaluates Safety of Triacylglycerol Lipase from Ruminant Pregastric Tissue
-
EFSA Unable to Conclude on Full-Scope Safety of Genetically Modified Oilseed Rape LBFLFK
-
Zimbabwe Blueberries Position for Growth Following China Market Access and Zero-Tariff Policy
-
Canada Proposes Revised Maximum Residue Limits for Pyrethrins and Penthiopyrad
-
Invista Reshuffles Global Nylon 66 Map: Shutting US and UK Plants, Betting Big on China—What Exactly Are They Aiming For?
-
Arkema Invests $60 Million to Upgrade its US FluoroSpecialties Production Unit
-
A White Storm Sweeps Through “Golden October”: China’s Titanium Dioxide Giants Join Forces in a Battle for SurvivalA White Storm Sweeps Through “Golden October”: China’s Titanium Dioxide Giants Join Forces in a Battle for Survival
Recommend Reading
-
Aspen Secures Approval to Market Lilly’s Mounjaro for Weight Loss in South Africa
-
J&J to Spin Off Orthopedics Business, Raises 2025 Forecast
-
Hormuz Is Reopening, But Chemical Logistics May Take Months to Recover
-
India Accuses Balaji Amines of Manufacturing Pharma-Grade Propylene Glycol Without Drug Manufacturing Licence
-
EFSA Evaluates Extended Use of Pasteurised Akkermansia muciniphila as a Novel Food
-
Resonance on Both Supply and Demand Sides Drives Continued Rise in Lithium Carbonate Prices
-
EVA Market Trends Narrowly Consolidate in the Short Term
-
This Week, the Chinese Polymeric MDI Market Showed a Weak Decline (4.20-4.24)
-
Downstream Replenishment: EVA Market Prices Have Slightly Risen Recently
-
August Lithium Carbonate Market Shows "Roller Coaster" Trend in China